Generalized pain with tender points in specific areas accompanied by systemic symptoms
such as fatigue and stiffness is characteristic of fibromyalgia (FM) syndrome. The genesis of
FM is still being investigated with conflicting data on factors including autonomic dysfunction,
neurotransmitters, and hormones often in combination with external stressful events. However,
recent research is starting to suggest that there is a previously underappreciated subtype of fibromyalgia
called inflammatory Fibromyalgia (iFM). Recent studies have described cytokines,
inflammatory markers, sleep disorders, hyperalgesia, cognitive dysfunction, serum leptin levels
and other inflammatory indicators as potential markers for iFM. This article will; 1) review the
inflammatory markers and abnormal levels of other laboratory indicators that can help to identify
the subgroup of patients that fall into the new category of Inflammatory Fibromyalgia [1-5] and 2)
review all completed trials that were focused on treating this new category of disease. Through
this review it is hoped that and further understanding of the complexity of the etiology of fibromyalgia
can be explored.
Keywords: Fibromyalgia, inflammation, cytokine, autonomic dysfunction, cytokines.
Rights & PermissionsPrintExport